HSG provides antitumor efficacy on hepatocellular carcinoma both in vitro and in vivo

Oncology Reports

Volumn 24, Issue 1, 2010, Pages 183-188

  Wang, Weilin ^a   Zhu, Feng ^a   Wang, Shuqian ^a   Wei, Jianfeng ^a   Jia, Changku ^a   Zhang, Yuanbiao ^a   Zhou, Lin ^a   Xie, Haiyang ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CYCLINE; HYPERPLASIA SUPPRESSOR PROTEIN; PROTEIN P21; PROTEIN P27; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MFN2 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; DRUG SCREENING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GTP PHOSPHOHYDROLASES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIAL PROTEINS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952980581     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000844     Document Type: Article

References (25)

1. Parkin DM, Bray B, Ferlay J, et al: Global cancer statistics. CA Cancer J Clin 55: 74-108, 2005.
2. Poon TP, Fan ST and Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24, 2000. (Pubitemid 30456545)
3. Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
4. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003.
5. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
6. Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
7. Pang RW and Poon RT: From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72: S30-S44, 2007.
8. Alcoceba RH, Sangro B and Prieto J: Gene therapy of liver cancer. World J Gastroenterol 12: 6085-6097, 2006.
9. Palmer DH, Hussain SA and Johnson PJ: Gene- and immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther 5: 507-523, 2005.
10. Chen KH, Guo X, Ma D, et al: Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 6: 872-883, 2004. (Pubitemid 39207252)
11. Srivastava S, Zou ZQ, Pirollo K, et al: Chang, Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-749, 1990.
12. Chen H, Detmer SA, Ewald AJ, et al: Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160: 189-200, 2003. (Pubitemid 36254953)
13. Guo X, Chen KH, Guo Y, et al: Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway. Circ Res 101: 1113-1122, 2007. (Pubitemid 350146437)
14. Ishihara N, Eura Y and Mihara K: Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. J Cell Sci 117: 6535-6546, 2004. (Pubitemid 40214575)
15. Karbowski M, Lee YJ, Gaume B, et al: Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol 159: 931-938, 2002. (Pubitemid 36055748)
16. Bagchi A and Mills AA: The quest for the 1p36 tumor suppressor. Cancer Res 68: 2551-2556, 2008.
17. Zborovskaia TA: Molecular markers of various stages of non-small cell lung cancer development. Mol Biol 38: 191-202, 2004. (Pubitemid 44245327)
18. Mori N, Morosetti R, Spira S, et al: Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 92: 3405-3409, 1998. (Pubitemid 28492351)
19. Smedley D, Sidhar S, Birdsall S, et al: Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer 28: 121-125, 2000. (Pubitemid 30176770)
20. Coleman WB: Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3: 573-588, 2003.
21. Feitelson MA, Sun B, Satiroglu NF, et al: Genetic mechanisms of hepatocarcinogenesis. Oncogene 21: 2593-2604, 2002.
22. Philipp-Staheli J, Payne SR and Kemp CJ: p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264: 148-168, 2001. (Pubitemid 32989089)
23. Fiorentino M, Altimari A, D'Errico A, et al: Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 6: 3966-3972, 2000.
24. Matsuda Y: Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J Gastroenterol 14: 1734-1740, 2008.
25. Gramantieri L, Trere D, Chieco P, Lacchini M, et al: In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. J Hepatol 39: 997-1003, 2003.